DNA vaccines are a promising therapeutic approach for personalized cancer immunotherapy. However, the application of therapeutic DNA-based cancer vaccines is still limited by their variable clinical ...

As drug developers face mounting pressure to accelerate discovery timelines without sacrificing quality, QLNS-CHO offers a compelling solution.

Extend transfection complex formation time by up to 3 hours, reduce complex volume by >50% and maintain high titers and full ...

BDNF CRISPR Activation Plasmid Transfection in hDPSCs DPSCs were incubated in a 6-well plate with 3 ml of antibiotic-free standard growth medium at 37°C in a 5% CO2 incubator until reaching 40-60% ...

imageimageAAVPureMfg produces high-purity AAV vectors with reduced plasmid cost, which holds tremendous clinical and commercial significance. Inherent limitations in triple transfection are elucidated ...

Thus far, scientists have produced approved therapies using triple-plasmid transient transfection and adherent cells. But many envision a future where producer cell lines will take over for large ...

Herein, live confocal microscopy was used to track plasmid DNA during transfection of Chinese hamster ovary (CHO) and human embryonic kidney (HEK) cells to map key cellular processes central to ...

Disease Insights The cancer segment dominated the viral vector and plasmid DNA manufacturing market with the largest share in 2024. This is primarily due to the rise in gene therapies for treating ...